Explorers on the frontier of
life-changing science.
At NGM, we are charting new paths and pushing beyond boundaries to develop medicines for people whose health and lives have been disrupted by disease.
NGM Bio has initiated its EMERALD Phase 2 Clinical Trial of NGM120 in Hyperemesis Gravidarum, also known as extreme pregnancy sickness.
Learn More About NGM120 and Hyperemesis Gravidarum
Our Pipeline
We are advancing NGM120, a GDF15/GFRAL antagonist antibody, to address two significant and distinct unmet needs, both of which are rooted in overactivation of the GDF15 pathway: hyperemesis gravidarum and cancer cachexia.
News Section